Your SlideShare is downloading. ×
Lesson 3 6 Laboratory Fdp
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Lesson 3 6 Laboratory Fdp


Published on

Med Lab

Med Lab

Published in: Health & Medicine, Technology

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Lesson 3-6 Rapid Hemostasis Tests
  • 2. Rapid Hemostasis Tests
    • Activated Clotting Time Plus (ACT+)
    • Heparin management test (HMT)
    • FDP and D-Dimer tests
  • 3. Use of Rapid Hemostasis Tests
    • Monitor heparin therapy
    • Identify
      • Disseminated Intravascular Coagulation (DIC)
      • Deep vein thrombosis (DVT)
      • Pulmonary embolism
  • 4. Activated Coagulation Time (ACT)
    • The ACT test evaluates coagulation status.
    • The ACT responds linearly to heparin level
    • changes and responds to wider ranges of
    • heparin concentrations than does the APTT.
    • The ACT, however, assays overall
    • coagulation activity. Therefore, prolonged
    • values may not be exclusively the result
    • of heparin.
  • 5. Normal
    • ACT: 70–120 seconds
    • Therapeutic range: 180–240 seconds
    • (two times normal range)
  • 6. Heparin Therapy
    • Action of heparin
      • Inhibits Factors IX, X, XI, and XII
      • Inhibits platelet release factor
    • Used to prevent thrombosis
  • 7. Tests for Heparin Effectiveness
    • ACT+
    • APTT
  • 8. Disseminated Intravascular Coagulation
    • Widespread thrombosis and hemorrhage
    • Due to:
      • Crush injuries
      • Certain infections
    • Coagulation factors and platelets become depleted
  • 9. Deep Vein Thrombosis and Pulmonary Embolism
    • DVT
      • Caused by slow blood flow
      • Thrombi form in lower extremities
    • Pulmonary Embolism
      • Complication of DVT
      • Thrombus dislodges and travels to lungs
      • Life threatening
  • 10. FDP and XDP
      • Fibrinogen/fibrin degradation products
      • Crosslinked fibrin derivatives
    When fibrin is split by plasmin, positive tests for fibrin degradation (split) products, identified by the letters X, Y, D, and E, are produced. These products have an anticoagulant action and inhibit clotting when they are present in excess in the circulation. Increased levels of FDPs may occur with a variety of pathologic processes in which clot formation and lysis occur. This test is done to establish the diagnosis of DIC and other thromboembolic disorders.
  • 11. FDP and XDP
  • 12. FDP and XDP
    • Formation
      • Plasmin cleaves fibrin and fibrinogen
      • Cleavage of stable clot forms XDP
      • D-dimer, another name for XDP
  • 13. Reference Values
    • Negative at 1:4 dilution or <10 µg/mL (<10 mg/L)
    Increased FSP and FDP are associated with DIC and are seen in: Venous thrombosis Primary fibrinolysis Thoracic and cradiac surgery or renal transplantation Acute myocardial infarction PE Carcinoma Liver disease
  • 14. FDP and XDP
    • Tests for FDP and XDP (D-dimer)
      • Manual latex agglutination tests
      • Instrumentation